CETP抗体

+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Immunofluorescence analysis of Hela cells using GLI1 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

  
  

•  

   

     Flow cytometric analysis of HepG2 cells using GLI1 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human ovarian cancer tissues using GLI1 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human esophageal cancer tissues using GLI1 mouse mAb with DAB staining.    

  
  

**Background of CETP Antibodies**

Cholesteryl ester transfer protein (CETP) is a plasma glycoprotein that facilitates the transfer of cholesteryl esters from anti-atherogenic high-density lipoproteins (HDL) to pro-atherogenic low-density lipoproteins (LDL) or very-low-density lipoproteins (VLDL). By regulating lipid exchange, CETP influences HDL and LDL cholesterol levels, making it a therapeutic target for cardiovascular diseases. Pharmacological inhibition of CETP aims to elevate HDL-C ("good cholesterol") while reducing LDL-C ("bad cholesterol"), potentially slowing atherosclerosis progression.

Traditional small-molecule CETP inhibitors (e.g., torcetrapib, anacetrapib) showed mixed clinical outcomes due to efficacy limitations or off-target effects. Recently, CETP-targeted monoclonal antibodies (mAbs) have emerged as alternatives, offering higher specificity and prolonged action. These antibodies bind CETP, blocking its lipid-transfer activity without interfering with protein synthesis. Preclinical studies suggest CETP mAbs effectively modulate lipid profiles and reduce plaque formation in animal models.

Current research focuses on optimizing antibody design and evaluating clinical safety. Early-phase trials of candidates like obicetrapib (TA-8993) demonstrate promising HDL-C elevation and LDL-C reduction. However, long-term cardiovascular outcomes and tolerability remain under investigation. CETP antibodies represent a novel approach to dyslipidemia management, potentially complementing statins and other lipid-lowering therapies in high-risk patients.